White House unveils nine new “most-favored-nation” drug pricing deals

most-favored-nation pricing; MFN; drug pricing; White House; Trump administration; pharmaceutical manufacturers; Ozempic; Wegovy; Eli Lilly; Novo Nordisk; prescription drug costs; US healthcare policy

The Endpoints 100: Biotech CEOs are feeling more upbeat about the road ahead

Endpoints 100; E100 survey; biotech CEOs; biopharma executives; industry sentiment; market recovery; dealmaking; IPO window; Trump administration; FDA reorganization; tariffs; 2025 outlook

Cigna Announces End to Drug Rebates for Many Health Plans Beginning in 2027

Cigna; drug rebates; pharmacy benefit manager; Evernorth; Express Scripts; upfront discounts; brand-name prescriptions; pharmacy reimbursement; Trump administration; drug pricing

White House Announces New Most-Favored Nation Drug Pricing Deal, Updates on FDA Vouchers and GLP-1 Negotiations

most-favored nation pricing; fertility drugs; IVF; Trump administration; drug pricing; Medicaid; FDA vouchers; GLP-1; EMD Serono; Pfizer; AstraZeneca

White House ‘Most Favored Nation’ Deadline Drives Pharma Concessions Amid Threats of Enforcement

most favored nation; drug pricing; White House; executive order; pharmaceutical companies; Medicaid; Medicare; drug manufacturers; Trump administration; prescription drug costs; deadline; pharma concessions